P
PPBT
vs
T
Tel Aviv 355
Over the past 12 months, PPBT has underperformed Tel Aviv 355, delivering a return of -81% compared to the Tel Aviv 355's +59% growth.
Stocks Performance
PPBT vs Tel Aviv 355
Performance Gap
PPBT vs Tel Aviv 355
Performance By Year
PPBT vs Tel Aviv 355
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.